Regentis Biomaterials’ GelrinC(R) Poised to Disrupt $3 Billion Knee Cartilage Repair Market with Off-the-Shelf Solution

Regentis Biomaterials Ltd. (NYSE American: RGNT) is emerging as a key player in orthopedic regenerative medicine with its GelrinC(R) platform, which could become the first true off-the-shelf solution for knee cartilage repair in the United States. The company is targeting an estimated $3 billion U.S. market with approximately 470,000 annual cases, and its product addresses a significant unmet need for a simple, effective, and cost-efficient treatment option.

GelrinC(R) is designed as a single-step procedure that integrates seamlessly into standard surgical workflows, eliminating the complexities and delays associated with cell-based therapies. Clinical data demonstrate that GelrinC(R) provides approximately 100% greater pain improvement compared to microfracture, the current standard of care, along with durable outcomes and MRI-confirmed regeneration of near-native cartilage. The procedure itself takes about 10 minutes, with a recovery period of roughly two weeks, offering substantial advantages over longer and more invasive alternatives.

The product is already CE Mark approved in Europe and is advancing through a pivotal Phase III clinical trial in the U.S., positioning the company for key catalysts including commercialization and FDA submission. With no comparable ready-to-use competitor in the market, GelrinC(R) has strong potential for adoption among surgeons, payers, and patients. Its lower cost profile relative to cell-based therapies further supports widespread use.

Regentis Biomaterials’ focus on knee injuries and other orthopedic applications leverages its Gelrin(TM) platform technology, which is based on synchronized, degradable materials that support tissue regeneration. For more information, visit the company’s newsroom at https://ibn.fm/RGNT.

This announcement comes via InvestorWire, a specialized communications platform for press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @IBN, which provides access to a vast network of wire solutions, article syndication to thousands of outlets, and enhanced press release distribution. For more details, see their disclaimer at https://www.InvestorWire.com/Disclaimer.